Key Takeaways JNJ will report Q2 earnings on July 16, with sales and EPS estimates at $22.79B and $2.66, respectively. Growth in key drugs like Darzalex and Tremfya will likely offset declines from Stelara and Imbruvica. MedTech faces challenges in China, but Abiomed, Shockwave and new products may support growth.Johnson & Johnson (JNJ) will begin the earnings season for the drug & biotech sector when it reports its second-quarter 2025 results on July 16. The Zacks Consensus Estimate for second-quarter sa ...